LFST Earnings

LFST reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 363.81M against an estimate of 355.03M, resulting in a 2.47% surprise. The EPS was 0, surpassing the expected -0.01 by 100%. The stock experienced a 29.94% price change on the earnings day and a 34.51% change over the next five days, reflecting market reactions to the results.

Following LFST's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 29.94% on the day of the release. Over the subsequent five days, it saw a 34.51% change. Historically, LFST's stock price tends to shift by an average of -3.31% in the 10 days leading up to earnings and -0.24% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate LFST's annual revenue to reach 381.48M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LFST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LFST's stock price typically moves by -3.31% in the 10 days before its earnings and -0.24% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.00 and revenue of 381.48M.

The earnings call highlights strong financial performance with raised EBITDA guidance, anticipated revenue growth, and margin expansion. Product development and technology integration are promising, supported by AI initiatives and specialty services. The Q&A section confirms durable productivity improvements and strategic focus on efficiency and clinician retention. While some areas lack specific detail, the overall sentiment is positive, driven by constructive payer relationships and optimistic long-term growth projections. Given the small-cap nature of the stock, a positive reaction of 2% to 8% is expected over the next two weeks.